MK-2870-032 A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer by Mary Beth Wilwerding | Sep 2, 2026
OPERA-01 A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and cdk 4/6 inhibitor therapy by Mary Beth Wilwerding | Sep 2, 2026
A012103 OptimICE-PCR: De-escalation of Therapy in Early -stage TNBC Patient who achieve PCR After Neoadjuvant Chemotherapy with Check point inhibitor Therapy by Mary Beth Wilwerding | Aug 19, 2026
RLY-2608-102 A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor by Mary Beth Wilwerding | Aug 19, 2026
RYZ-101-201 Phase 1b/2 open-label trial of Ac225 Dotatate (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-, unrecsectable or metastatic breast cancer expressing SSTRs and progressed after antibody-drug conjugates and/or chemotherapy. by Mary Beth Wilwerding | Aug 19, 2026
